30,000 volunteers - and counting!

Posted:
17
September 2004

Today we are celebrating after successfully recruiting our 30,000th clinical trial volunteer. This major milestone has been reached in just two and a half years, demonstrating that we continue to lead the market in volunteer recruitment.Wendy Galloway, head of Volunteer Recruitment, commented: “We are all delighted to have recruited 30,000 volunteers in such a short period of time, and I would like to thank everyone within our dedicated volunteer recruitment team for making this possible. I would also like to thank the hundreds of volunteers who participate in our trials every month — we appreciate that their full co-operation is pivotal to any study, which is why we make the time they spend staying in our wards as safe, comfortable and enjoyable as possible.”Our highly motivated volunteer recruitment team consistently recruits over 1,000 volunteers a month. We have an integrated sales and marketing approach to recruitment, including targeted advertising campaigns and our dedicated recruitment website www.trials4us.co.uk.Due to the increasing number of studies conducted by Richmond, the volunteer recruitment team is constantly building upon our impressive volunteer database to ensure that all study recruitment targets are met. The database encompasses a wide range of populations, for instance 14% of the database are healthy volunteers aged 60 years or above. We guarantee volunteer panels for all our clients. For more information visit our volunteer recruitment section.

Trials4us

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more